SERIS Trademark

Trademark Overview

On Friday, February 27, 2026, a trademark application was filed for SERIS with the United States Patent and Trademark Office. The USPTO has given the SERIS trademark a serial number of 99673451. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Friday, February 27, 2026. This trademark is owned by Shennon Biotechnologies. The SERIS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific research and development; Drug screening for scientific research purposes; Toxicology testing for research purposes
seris

General Information

Serial Number99673451
Word MarkSERIS
Filing DateFriday, February 27, 2026
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateFriday, February 27, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesScientific research and development; Drug screening for scientific research purposes; Toxicology testing for research purposes

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, February 27, 2026
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameShennon Biotechnologies
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Francisco, CA 94107
US

Trademark Events

Event DateEvent Description
Friday, February 27, 2026NEW APPLICATION ENTERED
Friday, February 27, 2026APPLICATION FILING RECEIPT MAILED

Related Keywords

seris research scientific purposes toxicology testing drug development screening